Cargando…
Global Prioritization of Disease Candidate Metabolites Based on a Multi-omics Composite Network
The identification of disease-related metabolites is important for a better understanding of metabolite pathological processes in order to improve human medicine. Metabolites, which are the terminal products of cellular regulatory process, can be affected by multi-omic processes. In this work, we pr...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657017/ https://www.ncbi.nlm.nih.gov/pubmed/26598063 http://dx.doi.org/10.1038/srep17201 |
_version_ | 1782402317988921344 |
---|---|
author | Yao, Qianlan Xu, Yanjun Yang, Haixiu Shang, Desi Zhang, Chunlong Zhang, Yunpeng Sun, Zeguo Shi, Xinrui Feng, Li Han, Junwei Su, Fei Li, Chunquan Li, Xia |
author_facet | Yao, Qianlan Xu, Yanjun Yang, Haixiu Shang, Desi Zhang, Chunlong Zhang, Yunpeng Sun, Zeguo Shi, Xinrui Feng, Li Han, Junwei Su, Fei Li, Chunquan Li, Xia |
author_sort | Yao, Qianlan |
collection | PubMed |
description | The identification of disease-related metabolites is important for a better understanding of metabolite pathological processes in order to improve human medicine. Metabolites, which are the terminal products of cellular regulatory process, can be affected by multi-omic processes. In this work, we propose a powerful method, MetPriCNet, to predict and prioritize disease candidate metabolites based on integrated multi-omics information. MetPriCNet prioritized candidate metabolites based on their global distance similarity with seed nodes in a composite network, which integrated multi-omics information from the genome, phenome, metabolome and interactome. After performing cross-validation on 87 phenotypes with a total of 602 metabolites, MetPriCNet achieved a high AUC value of up to 0.918. We also assessed the performance of MetPriCNet on 18 disease classes and found that 4 disease classes achieved an AUC value over 0.95. Notably, MetPriCNet can also predict disease metabolites without known disease metabolite knowledge. Some new high-risk metabolites of breast cancer were predicted, although there is a lack of known disease metabolite information. A predicted disease metabolic landscape was constructed and analyzed based on the results of MetPriCNet for 87 phenotypes to help us understand the genetic and metabolic mechanism of disease from a global view. |
format | Online Article Text |
id | pubmed-4657017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46570172015-11-30 Global Prioritization of Disease Candidate Metabolites Based on a Multi-omics Composite Network Yao, Qianlan Xu, Yanjun Yang, Haixiu Shang, Desi Zhang, Chunlong Zhang, Yunpeng Sun, Zeguo Shi, Xinrui Feng, Li Han, Junwei Su, Fei Li, Chunquan Li, Xia Sci Rep Article The identification of disease-related metabolites is important for a better understanding of metabolite pathological processes in order to improve human medicine. Metabolites, which are the terminal products of cellular regulatory process, can be affected by multi-omic processes. In this work, we propose a powerful method, MetPriCNet, to predict and prioritize disease candidate metabolites based on integrated multi-omics information. MetPriCNet prioritized candidate metabolites based on their global distance similarity with seed nodes in a composite network, which integrated multi-omics information from the genome, phenome, metabolome and interactome. After performing cross-validation on 87 phenotypes with a total of 602 metabolites, MetPriCNet achieved a high AUC value of up to 0.918. We also assessed the performance of MetPriCNet on 18 disease classes and found that 4 disease classes achieved an AUC value over 0.95. Notably, MetPriCNet can also predict disease metabolites without known disease metabolite knowledge. Some new high-risk metabolites of breast cancer were predicted, although there is a lack of known disease metabolite information. A predicted disease metabolic landscape was constructed and analyzed based on the results of MetPriCNet for 87 phenotypes to help us understand the genetic and metabolic mechanism of disease from a global view. Nature Publishing Group 2015-11-24 /pmc/articles/PMC4657017/ /pubmed/26598063 http://dx.doi.org/10.1038/srep17201 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Yao, Qianlan Xu, Yanjun Yang, Haixiu Shang, Desi Zhang, Chunlong Zhang, Yunpeng Sun, Zeguo Shi, Xinrui Feng, Li Han, Junwei Su, Fei Li, Chunquan Li, Xia Global Prioritization of Disease Candidate Metabolites Based on a Multi-omics Composite Network |
title | Global Prioritization of Disease Candidate Metabolites Based on a Multi-omics Composite Network |
title_full | Global Prioritization of Disease Candidate Metabolites Based on a Multi-omics Composite Network |
title_fullStr | Global Prioritization of Disease Candidate Metabolites Based on a Multi-omics Composite Network |
title_full_unstemmed | Global Prioritization of Disease Candidate Metabolites Based on a Multi-omics Composite Network |
title_short | Global Prioritization of Disease Candidate Metabolites Based on a Multi-omics Composite Network |
title_sort | global prioritization of disease candidate metabolites based on a multi-omics composite network |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657017/ https://www.ncbi.nlm.nih.gov/pubmed/26598063 http://dx.doi.org/10.1038/srep17201 |
work_keys_str_mv | AT yaoqianlan globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT xuyanjun globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT yanghaixiu globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT shangdesi globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT zhangchunlong globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT zhangyunpeng globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT sunzeguo globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT shixinrui globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT fengli globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT hanjunwei globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT sufei globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT lichunquan globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork AT lixia globalprioritizationofdiseasecandidatemetabolitesbasedonamultiomicscompositenetwork |